Crossmark

Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH

Crossref DOI link: https://doi.org/10.1016/j.aohep.2025.102143

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Jermy, Bradley

Brownrigg, Jack

Strnad, Pavel

Loomba, Rohit
Funding

Funding for this research was provided by:

NHLBI (P01HL147835)

Deutsche Forschungsgemeinschaft (STR1095/6-1)

Deutsche Forschungsgemeinschaft (SFB 1382)

NIDDK (R01DK106419)

NIDDK (P30DK120515)

NIDDK (R01DK124318)

NIDDK (U01DK061734)

NIDDK (U01DK130190)

NIDDK (R01DK121378)

BioMarin Pharmaceutical

NCATS (5UL1TR001442)
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2025-10-20
More Information

This article is maintained by: Elsevier

Article Title: Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2025.102143

Content Type: article

Copyright: © 2025 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U.